- Covaccin trial for children to start in AIIMS Delhi
- Initially, the BB vaccine will be tested on children between the ages of 12 and 18.
- Covaxin has already been approved for use on adults
- Bharat Biotech has made this vaccine, ICMR researchers also included
The trial of Covaxin, the first Kovid-19 vaccine developed in India, is about to start on children. Screening for this at AIIMS Delhi started on Monday. Volunteers in the age group of 2 years to 18 years will be included in this trial. The trial of this
This trial will be done on 525 healthy volunteers. According to the news agency PTI, once the screening report comes, the first dose of the vaccine will be given. During the trial, two doses of the vaccine will be taken. The second dose will be administered after 28 days.
What Happens in Screening for a Vaccine Trial?
- Anyone who wants to participate in the trial has to approach the agency conducting the trial. Since this trial is being conducted on children, written permission of their parents/guardian would be necessary.
- Only those children who will be healthy will be included in the trial.
- A form will be given to the Guardian. In it, many information related to the child will be asked.
- If there is any kind of medical history, then its details will have to be given.
- In the absence of any kind of physical discomfort which hinders the trial, he cannot appear in the trial.
- A declaration will also be required to state that you (Guardian) have been informed of the trial process and that you agree to it.
- Approval has to be given to collect and store the blood/tissue samples of children.
- All volunteers will have Kovid-19 and antibody test. You can join the trial only if it comes negative.
ICMR-BB has jointly made Covaxin
Covaxin has been developed by Hyderabad-based Bharat Biotech in association with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). Covaxin is an ‘inactivated’ vaccine. It is made from the dead particles of those corona virus. Its dosage makes antibodies against the virus in the body. These antibodies protect the body from corona infection.
Trials have already started in AIIMS Patna (File)